Huntington’s disease: A comprehensive case report
Department of Pharmacy Practice, Chalapathi institute of pharmaceutical sciences, Guntur, Andhra Pradesh, India.
Review
World Journal of Biology Pharmacy and Health Sciences, 2024, 17(03), 252–253.
Article DOI: 10.30574/wjbphs.2024.17.3.0139
Publication history:
Received on 07 February 2024; revised on 16 March 2024; accepted on 19 March 2024
Abstract:
Chorea form movements, neuropsychiatric symptoms, and cognitive impairment are hallmarks of Huntington's disease, an inherited progressive neurodegenerative illness that results in severe functional impairment. Between the ages of 30 and 40, it typically shows up. The genetic components of the disease are inherited, meaning that the afflicted individual receives the gene from a parent with the same genetic makeup. It is inherited in an autosomal-dominant manner. It is brought on by increased cytosine-adenine-guanine (CAG) tri-nucleotide repeat in Huntington’s (HTT) gene on chromosome 4p. A patient with a strong family history of Huntington's disease is described, associated with their clinical and genetic features.
Keywords:
Huntington's disease; Supportive therapy; Polymorphic tri nucleotide; Caudate head atrophy
Full text article in PDF:
Copyright information:
Copyright © 2024 Author(s) retain the copyright of this article. This article is published under the terms of the Creative Commons Attribution Liscense 4.0